This degrader, employing an RNA aptamer, effectively inhibited proliferation in various lung and breast cancer cells with p53-R175H mutation, while leaving wild-type p53 and other p53 mutants unaffected and promoting p53 downstream effectors.470 Moreover, the reactivated p53 was observed in PROTACs targeting MDM2 or BRD4, as discussed in the relevant section. Here, TP53 is linked to breast carcinoma.